{"Clinical Trial ID": "NCT00074152", "Intervention": ["INTERVENTION 1:", "Bras I", "Observation (+/- Radiation) Patients receive radiation therapy* within 6 months of surgery.", "Radiotherapy: given within 6 months of surgery", "INTERVENTION 2:", "Army II", "Within 10 weeks of surgery, patients receive at least 3 adjuvant chemotherapy treatments, as determined by the investigator. Patients may receive radiotherapy within 6 months of surgery and after completion of OR integrated chemotherapy.", "Chemotherapy: administered within 10 weeks of surgery."], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "Invasive breast cancer confirmed histologically", "The first local and/or regional recurrence (i.e. ipsilateral or internal breast axillary lymphatic region) after primary mastectomy or lumpectomy/quadrantectomy treatment with clear surgical margins", "A local failure is defined as a tumour recurrence in any soft tissue of the preserved ipsilateral breast or chest wall, mastectomy scar and/or skin", "Regional failure is defined as a tumour recurrence in the ipsilateral axillary lymph nodes, the ipsilateral axle soft extranodal tissue and/or the ipsilateral internal breast. Regional failure does not include supraclavicular lymph nodes or tumour in the opposite breast.", "No previous recurrence at any site, including local", "\u2022 Surgical resection of recurrence meeting 1 of the following criteria:", "\"Clear\" margins and planned radiation therapy with at least 40 Gy for patients who did not have previous adjuvant radiation therapy.", "A mastectomy of recurrence with uni-implicited margins (\"light\") after lumpectomy/quadrantectomy alone for primary", "In patients with HER-2-positive tumours, treatment with adjuvant trastuzumab (Herceptin\u00ae) or other HER-2-directed treatments is permitted and should be reported prior to randomisation.", "No distant metastasis, including ipsilateral supraclavcular lymph nodes, by X-ray or chest scan, ultrasound or scanning of abdomen and pelvis, or bone scintigraphy only if alkaline phosphatase is > 2 times normal or if medically indicated (e.g. bone pain)", "No incomplete macroscopic surgery", "No bilateral malignancy except in situ carcinoma", "No suspicious mass in the opposite breast unless this mass has been proven by biopsy to be benign", "No skeletal pain of unknown cause", "No hot spot on the bone scan for which metastases cannot be excluded by X-ray, MRI and/or CT scan", "- Hormonal receptor status:", "Determined in the recurrent tumour by immunohistochemistry and/or ligand-liding test", "Positive or negative estrogen receptor", "Positive or negative progesterone receptor", "CHARACTERISTICS OF PATIENTS:", "Age", "At least 18 years of age", "Gender", "Women", "Status of menopause", "Unspecified", "State of play", "Unspecified", "Life expectancy", "Unspecified", "Haematopoietic", "Unspecified", "Hepatic", "No high alkaline phosphatase", "Renal", "Unspecified", "Other", "Fertile patients should use effective non-hormonal contraception", "Medically appropriate for chemotherapy from 3 to 6 months", "No other primary malignant tumours except a carcinoma properly treated in situ for cervical or non-melanoma cancer", "No non-malignant systemic disease that would prevent treatment under study or prolong follow-up", "No psychiatric or addictive disorder that would prevent informed consent from being given", "There is no history of non-compliance with medical plans or there is a risk that it will be unreliable.", "THERAPE PRIOR CONCURENT:", "Biological therapy", "Unspecified", "- Chemotherapy", "See Disease Characteristics", "Endocrinotherapy", "Unspecified", "Radiotherapy", "See Disease Characteristics", "Surgery", "See Disease Characteristics"], "Results": ["Performance measures:", "\u2022 Disease-free survival", "[Unspecified]", "Time limit: 5 years after randomisation", "Results 1:", "Title of the arm/group: Arm I", "- Description of the arm/group: Observation (+/- Radiation) Patients receive radiation therapy* within 6 months of surgery.", "Radiotherapy: given within 6 months of surgery", "Total number of participants analysed: 77", "Type of measurement: Number", "Unit of measure: percentage of participants 57 (44 to 67)", "Results 2:", "Title of arm/group: Arm II", "Within 10 weeks of surgery, patients receive at least 3 adjuvant chemotherapy treatments, as determined by the investigator. Patients may receive radiotherapy within 6 months of surgery and after completion of chemotherapy OR integrated with chemotherapy.", "Chemotherapy: administered within 10 weeks of surgery.", "Total number of participants analysed: 85", "Type of measurement: Number", "Unit of measure: percentage of participants 69 (56-79)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/77 (0.00 per cent)", "- Neutropenia [1]0/77 (0.00 %)", "Left ventricular dysfunction 0/77 (0.00 %)", "- Cardiac ischemia 0/77 (0.00 %)", "Gastrointestinal pain 0/77 (0.00 %)", "- Collite 0/77 (0.00 %)", "- Febrile neutropenia 0/77 (0.00 %)", "- Pulmonary/superior respiratory tract infection 0/77 (0.00 %)", "- Diverticulitis 0/77 (0.00 %)", "- Motor neuropathy 0/77 (0.00 %)", "Endometrial mucosal thought 0/77 (0.00 %)", "Adverse Events 2:", "Total: 12/85 (14.12 per cent)", "Neutropenia [1]1/85 (1.18 %)", "Left ventricular dysfunction 1/85 (1.18 %)", "2/85 (2,35%)", "Gastrointestinal pain 1/85 (1.18 %)", "Colite 1/85 (1.18 per cent)", "- Febrile neutropenia 3/85 (3.53%)", "1/85 (1.18 %)", "Diverticulitis 1/85 (1.18 %)", "1/85 (1.18 %)", "Endometrial mucosa thought 1/85 (1.18 %)"]}